KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Gross Margin (2017 - 2025)

Sarepta Therapeutics (SRPT) has 8 years of Gross Margin data on record, last reported at 112.77% in Q4 2024.

  • For Q4 2024, Gross Margin rose 2230.0% year-over-year to 112.77%; the TTM value through Dec 2024 reached 61.63%, down 2300.0%, while the annual FY2024 figure was 179.86%, 26777.0% down from the prior year.
  • Gross Margin reached 112.77% in Q4 2024 per SRPT's latest filing, up from 91.61% in the prior quarter.
  • Across five years, Gross Margin topped out at 112.77% in Q4 2024 and bottomed at 77.6% in Q3 2022.
  • Average Gross Margin over 5 years is 70.54%, with a median of 86.91% recorded in 2020.
  • Peak YoY movement for Gross Margin: tumbled -16757bps in 2022, then soared 15621bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 63.21% in 2020, then grew by 13bps to 71.65% in 2021, then rose by 14bps to 81.8% in 2022, then rose by 11bps to 90.47% in 2023, then increased by 25bps to 112.77% in 2024.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 112.77% in Q4 2024, 91.61% in Q3 2024, and 87.65% in Q2 2024.